CA
NZ
UK
AU
IND
US
● ENDRA Life Sciences, a pre-revenue medical-imaging developer facing Nasdaq delisting, has agreed to merge with ASP Isotopes' Noble Africa unit and raise roughly $50 million, transforming into a helium-focused holding company renamed Noble Africa Inc.
● enVVeno Medical won a new U.S. patent covering its enVVe transcatheter venous valve days after securing FDA clearance to begin a pivotal trial, a rare string of good news for a company still recovering from the outright rejection of its earlier surgical valve, …
● Ernexa Therapeutics says an outside lab reproduced its ovarian-cancer cell-therapy data, with 10 of 15 treated animals achieving complete tumor clearance. The formerly named Eterna Therapeutics is racing toward an IND filing while trading near a $4 million market value after a 1-for-25 …
● Evogene said its ChemPass AI drug- and crop-chemical-design engine reached a new milestone with Google Cloud, embedding autonomous AI agents built on Gemini into its molecule-discovery workflow. The advance comes as the Israeli computational-biology company reports just $13.1 million in cash and shrinking …
● Costco's decision to drop FOCUSfactor after more than 16 years removes a customer that generated roughly 58% of Synergy CHC's 2025 revenue, compounding an already precarious cash position at the small-cap consumer-health company.
● Theriva Biologics reached a positive End-of-Phase 2 meeting with the FDA in March 2026, aligning on the design of a pivotal Phase 3 trial of oncolytic virus VCN-01 in metastatic pancreatic cancer, even as cash reserves remain modest and share dilution has been …
● First-quarter revenue at the sleep-apnea device maker rose 70.5% year over year on an acquisition-driven boost, but the same filings disclose a going-concern warning, a $13.1 million working-capital deficit, and a Nasdaq minimum-bid-price deficiency the company must cure by December 2, 2026.
● VolitionRx's Nu.Q nucleosomics platform has posted preliminary blinded-cohort data showing over 95% sensitivity for early-stage cancers, alongside fresh progress in sepsis and veterinary diagnostics. A stockholders'-equity deficiency, recurring dilutive financings and thin cash reserves complicate the story.
● Vyome Holdings, a small-cap dermatology and anti-infective developer pursuing a US-India strategy, disclosed a new Chinese patent and a licensing deal for two JAK inhibitor assets from Tata-backed Impetis Biosciences. The company frames the deal as tied to a $57 billion market, a …
● ZeroStack Corp., formerly cannabis-and-pharma distributor Flora Growth, disclosed new German pharmaceutical purchase orders worth up to $14.7 million just as it closed a transaction giving it roughly a fifth of the 0G cryptocurrency's total supply.
Please wait processing your request...